Retirement Systems of Alabama increased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 26.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 530,022 shares of the company's stock after buying an additional 112,286 shares during the quarter. Retirement Systems of Alabama owned 0.07% of Roivant Sciences worth $6,116,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of the business. Tyro Capital Management LLC boosted its position in Roivant Sciences by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock worth $20,252,000 after acquiring an additional 10,649 shares during the period. Te Ahumairangi Investment Management Ltd boosted its holdings in shares of Roivant Sciences by 19.9% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock worth $2,313,000 after purchasing an additional 33,467 shares during the period. Virtu Financial LLC acquired a new stake in shares of Roivant Sciences during the third quarter worth approximately $207,000. Geode Capital Management LLC grew its position in Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after purchasing an additional 1,460,205 shares in the last quarter. Finally, M&T Bank Corp acquired a new position in Roivant Sciences in the 3rd quarter valued at approximately $131,000. 64.76% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the transaction, the chief operating officer now owns 606,525 shares of the company's stock, valued at approximately $6,865,863. The trade was a 14.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew Gline sold 1,983,257 shares of the firm's stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the sale, the chief executive officer now directly owns 17,870,543 shares in the company, valued at $210,693,701.97. This trade represents a 9.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,677,309 shares of company stock valued at $43,283,184 over the last 90 days. 7.90% of the stock is currently owned by company insiders.
Roivant Sciences Price Performance
NASDAQ:ROIV traded down $0.19 during trading hours on Thursday, reaching $11.50. The company's stock had a trading volume of 7,366,581 shares, compared to its average volume of 5,754,815. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 2.04 and a beta of 1.25. The business's 50-day moving average is $11.92 and its 200-day moving average is $11.48. Roivant Sciences Ltd. has a one year low of $9.69 and a one year high of $13.06.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on ROIV shares. Bank of America lifted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $17.93.
View Our Latest Analysis on Roivant Sciences
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
